Fig. 1.

Knocking out HIF-1α expression in myeloid cells and systemic treatment during asthma induction with HIF-1α inhibitor YC-1 decreases AHR. a AHR was decreased in OVA HIF-1α KO mice (*P < 0.01, **P < 0.001). b AHR was the same in YC-1-treated mice as no-OVA controls (P > 0.05). Non-treated OVA controls had higher AHR than controls and YC-1-treated mice (*P < 0.01). c Treatment of OVA mice with YC-1 once, 1 h prior to MCH challenge, did not alter AHR. Both OVA and OVA + YC-1 × 1 groups had significantly higher AHR than no- OVA controls (*P < 0.05, **P < 0.001). Eight WT and 14 KO mice were used in our WT versus KO OVA mouse model of asthma, and four mice per group were used in our treatment models